Among patients with unresectable anaplastic thyroid cancer treated with lenvatinib, average survival was prolonged. The study was published as a preprint and has not yet been peer reviewed.
First Look
Among patients with unresectable anaplastic thyroid cancer treated with lenvatinib, average survival was prolonged. The study was published as a preprint and has not yet been peer reviewed.
First Look
